Words of Wisdom. Re: randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance.

Abstract

Expert’s summary: Although radical cystectomy is the recommended curative treatment for patients with muscle-invasive bladder cancer, many patients receive alternative therapies, such as chemotherapy or radiation. In this population-based study, Gore et al compared survival outcomes of invasive bladder cancer patients according to the treatment they received. Only 21% of patients underwent cystectomy. Patients whowere older, who had significant comorbidity, orwhohad to travel longdistances to a surgeon were less likely to have cystectomy. Overall survival was better for patients after cystectomy than for those who underwent alternative treatments.

DOI: 10.1016/j.eururo.2010.11.009

Cite this paper

@article{Rampersaud2011WordsOW, title={Words of Wisdom. Re: randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance.}, author={Edward N Rampersaud and Arie S. Belldegrun}, journal={European urology}, year={2011}, volume={59 2}, pages={301-2} }